EU extends Avastin OK to recurrent platinum-sensitive ovarian cancer
This article was originally published in Scrip
Executive Summary
Roche has as expected gained EU approval for Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and gemcitabine) to treat women with first recurrence of platinum-sensitive ovarian cancer. The European Commission's approval follows a positive recommendation for the indication by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in September (scripintelligence.com, 21 September 2012).